Daphné Provence de Riols de Fonclare

Ms. Daphné Provence de Riols de Fonclare

Université de Caen Normandie, Caen, Normandie, France
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2022 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
MFMatthieu Fritz
Matthieu Fritz
DFDaphné Provence de Riols de Fonclare
Daphné Provence de Riols de Fonclare
DGDéborah Garcia
Déborah Garcia
SBStéphanie Beurlet
Stéphanie Beurlet
PBPierre Becquart
Pierre Becquart
ELEric M. Leroy
Eric M. Leroy
We tested 144 pet rabbits sampled in France between November 2020 and June 2021 for antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by microsphere immunoassay. We reported the first evidence of a natural SARS-CoV-2 infection in rabbits with a low observed seroprevalence between 0.7% and 1.4%.

8 December 2024 in Zoonoses and Public Health
Verified
Journal Article
Open access
MFMatthieu Fritz
Matthieu Fritz
EEEric Elguero
Eric Elguero
PBPierre Becquart
Pierre Becquart
DFDaphné Provence de Riols de Fonclare
Daphné Provence de Riols de Fonclare
DGDéborah Garcia
Déborah Garcia
ELEric M. Leroy
Eric M. Leroy
Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has the potential to infect various animals, including domestic pets like dogs and cats. Many studies have documented infection in companion animals by molecular and serological methods. However, only a few have compared seroprevalence in cats and dogs from the general population, and these studies were limited by small sample sizes and collections over short periods. Our aim was to obtain a more accurate evaluation of seroprevalence in companion animals in France and to determine whether cats and dogs differ in their exposure to SARS‐CoV‐2.Methods: We conducted an extensive serological survey of SARS‐CoV‐2, collecting blood samples from 2036 cats and 3577 dogs during routine veterinary medical examinations across different regions of metropolitan France from October 2020 to June 2021. This period encompassed the peaks and onset of two waves, as well as the emergence of the first variants. A microsphere immunoassay targeting the receptor‐binding domain and trimeric spike protein was used to detect anti‐SARS‐CoV‐2 antibodies. A subset of 308 seropositive samples was tested for the presence of neutralising antibodies.Results: We determined an overall seroprevalence of anti‐SARS‐CoV‐2 antibodies of 7.1% (95% confidence interval [CI]: 6.4%–7.8%) among the sampled pets. Cats exhibited a significantly higher seroprevalence (9.3%; 95% CI: 8.1%–10.1%) compared to dogs (5.9%; 95% CI: 5.2%–6.8%). Among the subset of seropositive samples, 81 (26.3%; 95% CI: 21.5%–31.6%) displayed neutralizing antibodies. Furthermore, seroprevalence in both species was lower in older animals and was not associated with sex. Finally, unlike cats, seroprevalence in dogs was found to be correlated with the date of sampling.Conclusions: The large sample size enhances the reliability and statistical robustness of our estimates regarding pet exposure to SARS‐CoV‐2. This study on SARS‐CoV‐2 reaffirms the crucial importance of adopting a One Health approach incorporating domestic animals when managing an epidemic caused by a zoonotic virus.

9 April 2023 in Viruses
Verified
Journal Article
Open access
PDF file
LLLéadisaelle Hosanna Lenguiya
Léadisaelle Hosanna Lenguiya
MFMatthieu Fritz
Matthieu Fritz
DFDaphné Provence de Riols de Fonclare
Daphné Provence de Riols de Fonclare
SCSandrine Corbet
Sandrine Corbet
PBPierre Becquart
Pierre Becquart
FNFabien Roch Niama
Fabien Roch Niama
Following the emergence of SARS-CoV-2, cases of pets infected with variants circulating among humans were reported. In order to evaluate the occurrence of SARS-CoV-2 circulation among pets in the Republic of the Congo, we conducted a ten-month study of dogs and cats living in COVID-19-positive households in Brazzaville and neighboring localities. Real-time PCR and the Luminex platform were used to detect SARS-CoV-2 RNA and antibodies to SARS-CoV-2 RBD and S proteins, respectively. Our results show for the first time the simultaneous circulation of several variants of SARS-CoV-2, including viruses from clades 20A and 20H and a putative recombinant variant between viruses from clades 20B and 20H. We found a high seroprevalence of 38.6%, with 14% of tested pets positive for SARS-CoV-2 RNA. Thirty-four percent of infected pets developed mild clinical signs, including respiratory and digestive signs, and shed the virus for about one day to two weeks. These results highlight the potential risk of SARS-CoV-2 interspecies transmission and the benefits of a “One Health” approach that includes SARS-CoV-2 diagnosis and surveillance of viral diversity in pets. This approach aims to prevent transmission to surrounding wildlife as well as spillback to humans.

26 December 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
MFMatthieu Fritz
Matthieu Fritz
EEEric Elguero
Eric Elguero
PBPierre Becquart
Pierre Becquart
DFDaphné Provence de Riols de Fonclare
Daphné Provence de Riols de Fonclare
DGDéborah Garcia
Déborah Garcia
ELEric M. Leroy
Eric M. Leroy
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can infect many animals, including pets such as dogs and cats. Many studies have documented infection in companion animals by bio-molecular and serological methods. However, only a few have compared seroprevalence in cats and dogs from the general population, and these studies were limited by small sample sizes and collections over short periods. Our goal was to obtain a more accurate evaluation of seroprevalence in companion animals in France and to determine whether cats and dogs differ in their exposure to SARS-CoV-2. For this purpose, we conducted an extensive SARS-CoV-2 cross-sectional serological survey of 2036 cats and 3577 dogs sampled by veterinarians during medical examinations in clinics throughout France. Sampling was carried out from October 2020 through June 2021, a period encompassing the second and third waves of SARS-CoV-2 infections in humans in the country. Using a microsphere immunoassay targeting the receptor binding domain and trimeric spike protein, we found 7.1% seroprevalence in pets. In a subset of 308 seropositive samples, 26.3% had neutralizing antibodies. We found that cats were significantly more likely to test positive than dogs, with seropositivity rates of 9.3% and 5.9% in cats and dogs, respectively. Finally, data for both species showed that seroprevalence was lower in older animals and was not associated with the date of sampling or the sex of the animal. Our results show that cats are significantly more sensitive to SARS-CoV-2 than dogs, in line with experimental studies. Our large sample size provides for a reliable, statistically robust estimate of the frequency of infection of pets from their owners and offers strong support for the notion that cats are more sensitive to SARS-CoV-2 than dogs. Our findings emphasise the importance of a One-Health approach to the SARS-CoV-2 pandemic and raise the question of whether companion animals in close contact with humans should be vaccinated.

5 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
DFDaphné Provence de Riols de Fonclare
Daphné Provence de Riols de Fonclare
ASArtur Szczepanski
Artur Szczepanski
AMAleksandra Milewska
Aleksandra Milewska
SCSandrine Corbet
Sandrine Corbet
LRLucile Rouilly
Lucile Rouilly
MGMeriadeg Ar Gouilh
Meriadeg Ar Gouilh
Bats are recognized reservoirs for several zoonoses and have an exceptional tolerance to viruses, likely linked with strong evolutionary selection in immune genes. Notably, in light of the emergence history of severe acute respiratory syndrome coronavirus (SARS-CoV), SARS-CoV-2 is hypothesized to have originated from Rhinolophus bats as well. In-depth studies are still needed, however, to unravel how SARS-related coronaviruses (SARSr-CoVs) persist and thrive in nature through evolution, virus-host interactions, and cross-species transmission. Here we present a pioneering 10-year longitudinal study of BBCoV-EPI1, a SARSr-CoV in Rhinolophus bats that revealed the complexity of virus-host interactions and the tempo at which new viral lineages emerge. Our results demonstrated the impacts of host life cycles (hibernation, female gathering, weaning juveniles, and mating periods) on strong seasonal oscillations in viral prevalence. These pronounced fluctuations drove viral diversification through bottlenecks, founder effects and Darwinian selection, counterbalanced by high mutation rates, fast gradualism, and recombination. We also found that host-cell enzymes are major contributors to BBCoV-EPI1 evolution in bats. The antiviral effect of APOBEC3 detected here in bats is weaker than it is in humans. Conversely, the ADAR enzyme had an unexpectedly strong and beneficial influence on viral evolution, even though the high mutation rate of RNA viruses is usually attributed to viral polymerases′ low replication fidelity. We discovered that key BBCoV-EPI1 innovations in Rhinolophus bats were mostly located in proteins involved in cell-cycle hijack and in blocking bat cells′ antiviral response, rather than in the Spike (S). We also showed that the BBCoV-EPI1 S protein efficiently uses angiotensin-converting enzyme 2 (ACE2) receptor to enter Rhinolophus bat cells, but not to enter human or sympatric species cells, due to amino-acid differences at the S-ACE2 interface. Last, this work identifies 101 critical amino-acid changes frequently associated with viral fitness shift, and paves the way for future experimental studies focusing on the capacity of SARSr-CoVs to adapt to hosts and cross the species barrier.

7 July 2025
Verified
Preprint
Open access
PDF file
DFDaphné Provence de Riols de Fonclare
Daphné Provence de Riols de Fonclare
NDNefert-Candace Dossou
Nefert-Candace Dossou
SCSandrine Corbet
Sandrine Corbet
MGMeriadeg Ar Gouilh
Meriadeg Ar Gouilh
Ampliseq using nanopore design 2018 / 2019 This protocol is primarily intended for full viral genome sequencing and describes the preparation of an amplicon-based library for Nanopore sequencing using the NEBNext Ultra II DNA Library Prep Kit. It is highly adaptable to other targets, such as transcripts or genes of interest. It can be applied to any purified nucleic acid material containing RNA, or DNA in the case of genomic targets. It includes multiplex PCR amplification and several purification steps and ensures high specificity and uniform genome coverage. This version includes uracil-modified primers, which must be ordered specifically after primer design, as well as the associated Q5U polymerase and USER or FUPA enzymatic step to partially digest primers after amplification. However, the protocol can also be applied without U-modified primers, Q5U, USER, or FUPA by using standard primers, Q5 polymerase, and bioinformatic primer trimming. The only caution is to choose the primer-design strategy appropriately. The expected results include libraries with minimal amplification bias, enabling accurate variant detection in targeted genomic regions. This workflow enhances reproducibility and efficiency for amplicon-based sequencing applications.